About BreezeBio
BreezeBio is a rapidly-growing, early-stage company developing a proprietary and novel delivery platform with the potential to transform genetic medicine. Our interdisciplinary team works together across chemistry, payload design, formulation, and screening and preclinical groups to advance our NanoGalaxy® hydrophilic nanoparticle (HNP) platform toward a pipeline of therapeutic candidates. BreezeBio fosters an exciting and dynamic environment where we value impactful data and creative solutions.